Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D. Cartron G, et al. Among authors: sibon d. J Clin Oncol. 2023 Jul 1;41(19):3523-3533. doi: 10.1200/JCO.22.02327. Epub 2023 Apr 18. J Clin Oncol. 2023. PMID: 37071836 Free article. Clinical Trial.
[A medical-pharmaceutical partnership model as a contributor to the success in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults: a cross-reflection on our organizations].
Bourget P, Falaschi L, Suarez F, Galland V, Blot D, Trompette C, Sibon D, Fontbrune FS, Merlette C, Vidal F, Corriol O, Giraud B, Broissand C, Clement R, Hermine O. Bourget P, et al. Among authors: sibon d. Bull Cancer. 2012 Jun;99(6):643-53. doi: 10.1684/bdc.2012.1589. Bull Cancer. 2012. PMID: 22645281 Free article. French.
Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T, Suarez F, Marcais A, Sibon D, Buzyn A, Caillat-Zucman S, Cavazzana-Calvo M, Varet B, Dy M, Hermine O, Leite-de-Moraes M. Rubio MT, et al. Among authors: sibon d. Blood. 2012 Sep 6;120(10):2144-54. doi: 10.1182/blood-2012-01-404673. Epub 2012 Jun 22. Blood. 2012. PMID: 22730537 Free article.
Clinical trials of adult T-cell leukaemia/lymphoma treatment.
Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Marçais A, et al. Among authors: sibon d. Leuk Res Treatment. 2012;2012:932175. doi: 10.1155/2012/932175. Epub 2012 Feb 14. Leuk Res Treatment. 2012. PMID: 23213552 Free PMC article.
Therapeutic options for adult T-cell leukemia/lymphoma.
Marçais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A. Marçais A, et al. Among authors: sibon d. Curr Oncol Rep. 2013 Oct;15(5):457-64. doi: 10.1007/s11912-013-0332-6. Curr Oncol Rep. 2013. PMID: 23943384 Review.
Serotonin is a key factor for mouse red blood cell survival.
Amireault P, Bayard E, Launay JM, Sibon D, Le Van Kim C, Colin Y, Dy M, Hermine O, Côté F. Amireault P, et al. Among authors: sibon d. PLoS One. 2013 Dec 17;8(12):e83010. doi: 10.1371/journal.pone.0083010. eCollection 2013. PLoS One. 2013. PMID: 24358245 Free PMC article.
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas.
Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, Davi F, Settegrana C, Berger F, Alric L, Cacoub P, Terrier B, Suarez F, Sibon D, Dupuis J, Feray C, Tilly H, Pol S, Deau Fischer B, Roulland S, Thieblemont C, Leblond V, Carrat F, Hermine O, Besson C; national ANRS HC13 LymphoC study. Canioni D, et al. Among authors: sibon d. PLoS One. 2016 Jun 3;11(6):e0156384. doi: 10.1371/journal.pone.0156384. eCollection 2016. PLoS One. 2016. PMID: 27257992 Free PMC article.
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°. Cheminant M, et al. Among authors: sibon d. Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17. Gut. 2019. PMID: 30448772
86 results